← Research library

Thymopentin with oncolytic adenovirus in mouse tumor models

Animal research · 2026

What was studied
4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
Main finding
H22 liver tumor response and rechallenge · The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.

Reported findings and study design

Reported findings

Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.

Population or model 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.

Dose, route and schedule

Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.

Protocol source ↗ · Original full text, including study methods and Figures 1–5 and 7.

Results · Original full text, including study methods and Figures 1–5 and 7.
MeasureResultComparison, timing and statistics
H22 liver tumor response and rechallengeThe authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
Immune-cell dependenceThe combination increased cytotoxic CD8-positive T-cell and proinflammatory macrophage infiltration. Depletion of either cell population weakened the tumor response.
Engineered adenovirusThe thymopentin-expressing virus slowed tumor growth and prolonged survival in mouse experiments. The two viruses had similar replication and cell-killing behavior in the tested cell cultures.

All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.

Source details

Original full text, including study methods and Figures 1–5 and 7.

Sources checked

Added to the library

Citation

Animal / experimentalFull text available

L. Kong, K. Liu, Y. Liu, H. Cui, P. Wang, J. Qiu, Q. Xin, D. Zhou, W. Liu, F. Zhao, J. Wu, X. Gu, J. Wu, C. Jiang. Thymopentin with oncolytic adenovirus in mouse tumor models Communications Medicine 6, article 265

Study source ↗ · DOI 10.1038/s43856-026-01509-6 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards